Enhancing cancer treatment by targeting DNA repair mechanisms
Improving the therapeutic efficacy of chemoradiation by targeting the DNA damage response
This study is looking at ways to make cancer treatment more effective for people with advanced cancers by blocking the body's ability to repair damaged DNA in tumor cells, which could help the treatment work better while protecting healthy cells.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-10899781 on NIH RePORTER |
What this research studies
This research focuses on improving the effectiveness of chemoradiation therapy for patients with locally advanced cancers by targeting the DNA damage response (DDR) pathways. The approach aims to prevent the repair of DNA double strand breaks, which are critical for the success of chemoradiation. By inhibiting DDR, the researchers hope to make tumor cells more sensitive to treatment while sparing normal cells. The study also explores the potential of combining DDR inhibitors with immune checkpoint blockade therapy to enhance treatment outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with locally advanced cancers who are undergoing chemoradiation therapy.
Not a fit: Patients with early-stage cancers or those not receiving chemoradiation therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments that improve survival rates for patients with advanced cancers.
How similar studies have performed: Previous research has shown promising results in enhancing cancer treatment efficacy by targeting DNA damage response pathways, indicating that this approach has potential for success.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Parsels, Leslie Anne — University of Michigan at Ann Arbor
- Study coordinator: Parsels, Leslie Anne
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.